Eltrombopag
- Generic Name
- Eltrombopag
- Brand Names
- Promacta, Revolade
- Drug Type
- Small Molecule
- Chemical Formula
- C25H22N4O4
- CAS Number
- 496775-61-2
- Unique Ingredient Identifier
- S56D65XJ9G
- Background
Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also bee...
- Indication
Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction.
- Associated Conditions
- Chronic immune thrombocytopenia, Severe Aplastic Anemia (SAA), Thrombocytopenia
- Associated Therapies
- First-line Therapy
Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT05286164
- Locations
- 🇮🇱
Tel-Aviv Sourasky Medicak center / BMT Unit, Tel-Aviv, Israel
Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP
- Conditions
- Interventions
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 102
- Registration Number
- NCT04917679
- Locations
- 🇨🇳
Qilu hospital, Shandong University, Jinan, Shandong, China
MAP to Provide Access to Eltrombopag, for Treatment of Patients With Medically Significant Thrombocytopenia
- Conditions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04837703
Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence
- Conditions
- Interventions
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 35
- Registration Number
- NCT04797000
- Locations
- 🇯🇵
Novartis Investigative Site, Yamagata, Japan
Eltrombopag for Chemotherapy-induced Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2023-01-26
- Target Recruit Count
- 50
- Registration Number
- NCT04600960
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China
Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)
- Conditions
- Interventions
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 20
- Registration Number
- NCT04542382
- Locations
- 🇺🇸
Ucsf Ctsi Crc, San Francisco, California, United States
Fixed Low-dose Eltrombopag and rhTPO for Immune Thrombocytopenia (FLOWER)
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2020-09-01
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04518878
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
- Conditions
- Interventions
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2020-08-19
- Target Recruit Count
- 224
- Registration Number
- NCT04518475
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19)
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2020-09-01
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04516837
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 10
- Registration Number
- NCT04485416
- Locations
- 🇺🇸
University of California Davis Health System, Comprehensive Cancer Center, Sacramento, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.